Amwell cuts FY25 revenue view to $245M-$250M from $250M-$260M

Consensus $256.07M. Raises FY25 adjusted EBITDA loss view to $45M-$50M from $45M-$55M. The company said, “The company revised its guidance for 2025, which calls for: Revenue in the range of $245 million to $250 million, compared to previous guidance of $250 million to $260 million AMG visits between 1.3 million and 1.35 million, no change. The company also narrowed its guidance range for Adjusted EBITDA to a range of between (50) million to (45) million, the better part of the previous guidance of (55) million to (45) million.”